Allopurinol treatment adversely impacts left ventricular mass regression in patients with well-controlled hypertension.

ABSTRACT: OBJECTIVES:Previous studies have demonstrated that high-dose allopurinol is able to regress left ventricular (LV) mass in cohorts with established cardiovascular disease. The aim of this study was to assess whether treatment with high-dose allopurinol would regress LV mass in a cohort with essential hypertension, LV hypertrophy and well-controlled blood pressure but without established cardiovascular disease. METHODS:We conducted a mechanistic proof-of-concept randomized, placebo-controlled, double-blind trial of allopurinol (600 mg/day) versus placebo on LV mass regression. Duration of treatment was 12 months. LV mass regression was assessed by Cardiac Magnetic Resonance. Secondary outcomes were changes in endothelial function (flow-mediated dilatation), arterial stiffness (pulse wave vel

SUBMITTER: Gingles CR 

PROVIDER: S-EPMC6855336 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature